Three-gene prognostic classifier for early-stage non small-cell lung cancer.

PURPOSE Several microarray studies have reported gene expression signatures that classify non-small-cell lung carcinoma (NSCLC) patients into different prognostic groups. However, the prognostic gene lists reported to date overlap poorly across studies, and few have been validated independently using more quantitative assay methods. PATIENTS AND METHODS The expression of 158 putative prognostic genes identified in previous microarray studies was analyzed by reverse transcription quantitative polymerase chain reaction in the tumors of 147 NSCLC patients. Concordance indices and risk scores were used to identify a stage-independent set of genes that could classify patients with significantly different prognoses. RESULTS We have identified a three-gene classifier (STX1A, HIF1A, and CCR7) for overall survival (hazard ratio = 3.8; 95% CI, 1.7 to 8.2; P < .001). The classifier was also able to stratify stage I and II patients and further improved the predictive ability of clinical factors such as histology and tumor stage. The predictive value of this three-gene classifier was validated in two large independent microarray data sets from Harvard and Duke Universities. CONCLUSION We have identified a new three-gene classifier that is independent of and improves on stage to stratify early-stage NSCLC patients with significantly different prognoses. This classifier may be tested further for its potential value to improve the selection of resected NSCLC patients in adjuvant therapy.

[1]  M. Cronin,et al.  Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. , 2007, Clinical chemistry.

[2]  A. Dupuy,et al.  Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. , 2007, Journal of the National Cancer Institute.

[3]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[4]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[5]  I. Jurisica,et al.  Unequal evolutionary conservation of human protein interactions in interologous networks , 2007, Genome Biology.

[6]  Olivia W. Wilkins,et al.  Erratum: Genomic DNA functions as a universal external standard in quantitative real-time PCR (Nucleic Acids Research (2006) vol. 34 (e85)) , 2006 .

[7]  Zhifu Sun,et al.  A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer , 2006, PLoS medicine.

[8]  Catalin C. Barbacioru,et al.  Evaluation of DNA microarray results with quantitative gene expression platforms , 2006, Nature Biotechnology.

[9]  Eric P. Hoffman,et al.  Probe set algorithms: is there a rational best bet? , 2006, BMC Bioinformatics.

[10]  S. Mukherjee,et al.  A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. , 2006, The New England journal of medicine.

[11]  M. Tsao,et al.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation , 2006, Journal of Clinical Pathology.

[12]  Yi Zhang,et al.  Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. , 2006, Cancer research.

[13]  Olivia W. Wilkins,et al.  Genomic DNA functions as a universal external standard in quantitative real-time PCR , 2006, Nucleic acids research.

[14]  Ines Gockel,et al.  Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer. , 2006, Oncology reports.

[15]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[16]  Igor Jurisica,et al.  The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. , 2006, Cancer research.

[17]  L. Ein-Dor,et al.  Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Trevor Hastie,et al.  Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers , 2006, PLoS medicine.

[19]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[20]  Marcel J. T. Reinders,et al.  The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies , 2006, BMC Bioinformatics.

[21]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[22]  Richard Simon,et al.  Roadmap for developing and validating therapeutically relevant genomic classifiers. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Fata,et al.  Epimorphin overexpression in the mouse mammary gland promotes alveolar hyperplasia and mammary adenocarcinoma. , 2005, Cancer research.

[24]  R. Ramlau,et al.  Pr3 ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I–III) non small cell lung cancer (NSCLC) patients (pts) , 2005 .

[25]  J. Pignon,et al.  Adjuvant Chemotherapy for Non–Small Cell Lung Cancer: Contribution of the International Adjuvant Lung Trial , 2005, Clinical Cancer Research.

[26]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[27]  Sunil Singhal,et al.  Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A Review , 2005, Clinical Cancer Research.

[28]  P. Galle,et al.  Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer , 2005, Clinical Cancer Research.

[29]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[30]  I. Jurisica,et al.  Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. , 2004, Neoplasia.

[31]  I. Jurisica,et al.  Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. , 2004, Lung cancer.

[32]  I. Jurisica,et al.  Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis , 2004, Oncogene.

[33]  R. Schilsky,et al.  Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Shuta Tomida,et al.  Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients , 2004, Oncogene.

[35]  Jun Chen,et al.  Joint analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes , 2004, BMC Bioinformatics.

[36]  Giovanni Parmigiani,et al.  A Cross-Study Comparison of Gene Expression Studies for the Molecular Classification of Lung Cancer , 2004, Clinical Cancer Research.

[37]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[38]  Y. Yatabe,et al.  Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  I. Takanami.  Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis , 2003, International journal of cancer.

[40]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[41]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[42]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[43]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.

[44]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[45]  Igor Jurisica,et al.  Binary tree-structured vector quantization approach to clustering and visualizing microarray data , 2002, ISMB.

[46]  H. Stein,et al.  Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum , 2002, Virchows Archiv.

[47]  M. Tyers,et al.  Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. , 2002, Cancer research.

[48]  F. Tanaka,et al.  Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. , 2002, Cancer research.

[49]  C. Mountain,et al.  Staging classification of lung cancer. A critical evaluation. , 2002, Clinics in chest medicine.

[50]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[51]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[52]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  H. Höfler,et al.  Expression of vesicular monoamine transporters, synaptosomal-associated protein 25 and syntaxin1: a signature of human small cell lung carcinoma. , 2001, Cancer research.

[55]  H. Wada,et al.  Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[56]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[57]  R. Tsuchiya,et al.  Prognosis and survival in resected lung carcinoma based on the new international staging system. , 1988, The Journal of thoracic and cardiovascular surgery.